everolimus + mycophenolate mofetil

Everolimus + mycophenolate mofetil is a combination of two immunosuppressive agents used primarily to prevent organ transplant rejection, especially in kidney, heart, and liver transplantation. Everolimus is an mTOR inhibitor that suppresses T-cell activation and proliferation by inhibiting the mammalian target of rapamycin pathway. Mycophenolate mofetil is a prodrug of mycophenolic acid and acts as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking de novo guanosine nucleotide synthesis in T and B lymphocytes. This dual mechanism results in potent suppression of immune responses involved in graft rejection[2][6][8]. Both drugs are often used together or with other immunosuppressants to reduce the risk of acute or chronic allograft rejection.

Brand names

Certican

Other names

MMF (for mycophenolate mofetil)